TLR7 and basal cell carcinoma: Because they can mediate the anti-tumor effect, TLR agonists such as imiquimod, which activates TLR7/8 pathways, have been approved by the U.S. Food and Drug Administration (FDA) to treat patients with basal cell carcinomas [34].